Company Profile

Name

Organogenesis Inc.

Descriptor

A leading regenerative medicine company with the unique skill set to take complex, living therapies from research and development (R&D), through manufacturing, to successful commercialization.

Mission

To bring the medical marvel of regenerative medicine to patients and to standardize its use in everyday medical care

Founded

1985

Head Office

150 Dan Road
Canton, Massachusetts
02021
Google Maps

Fax: 781-575-1570
General Telephone number: (781) 575-0775

Organogenesis Switzerland Gmbh
Baarerstrasse 2
CH-6304 Zug
Switzerland
Telephone: +41 41 727 67 89

Major Milestones

1998: First FDA approval of a living, allogeneic, cell based product (Apligraf^® approved for the treatment of venous leg ulcers).

2000: Apligraf^® FDA approved for the treatment of diabetic foot ulcers.

2004: Launch of full USA sales and marketing organization.

2005: Over 120,000 patients treated with a living, cell based therapy.

2006: European office established.

2007: BioSTAR^® EU and Canadian approval and 200,000 patient applications of Apligraf^®.

Employees

1. Over 300 employees in USA
2. The executive team is comprised of talented individuals with over 100 years of collective regenerative medicine experience.

Areas of Focus

Three pillars:

1. Bio-active wound healing
2. Bio-aesthetics™
3. Bio-surgery

Key Pipeline Products

Multiple brands in active development in each of our three pillars of business.